Laura Biganzoli1, Lorenza Marotti2, Maria-Joao Cardoso3, Luigi Cataliotti4, Giuseppe Curigliano5,6, Jack Cuzick7, Aaron Goldhirsch8,9, Marjut Leidenius10, Robert Mansel11, Christos Markopoulos12, Lynda Wyld13, Isabel T Rubio14,15. 1. Breast Unit, Nuovo Ospedale di Prato, Prato, Italy. 2. EUSOMA, Florence, Italy. 3. Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal. 4. BCCERT and SENONETWORK Italia, Florence, Italy. 5. Department of Oncology and Haematology, University of Milan, Milan, Italy. 6. IEO, European Institute of Oncology IRCCS, Milan, Italy. 7. Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom. 8. International Breast Cancer Study Group, Bern, Switzerland. 9. MultiMedica, Milan, Italy. 10. Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. 11. Cardiff University School of Medicine, Cardiff, United Kingdom. 12. Medical School, National and Kapodistrian University of Athens, Athens, Greece. 13. Department of Oncology and Metabolism, University of Sheffield, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom. 14. Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Madrid, Spain. 15. Universidad de Navarra, Pamplona, Spain.
Abstract
BACKGROUND: EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres. SUMMARY: The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Based on the EUSOMA requirements, a voluntary and accredited certification scheme has been developed. In Europe, other voluntary certification schemes are available, such as those developed by the German Cancer Society and German Society for Breast Disease, the National Cancer Peer Review Programme in the UK, and the "label de qualité" established by the Swiss Anticancer League and the Swiss Senology Society. The European Commission Initiative on Breast Cancer (ECIBC) has overseen the development of a European Quality Assurance Scheme. KEY MESSAGES: Nearly 20 years after the initial publication of the EUSOMA requirements, ensuring that all breast cancer patients in Europe are treated only in certified breast centres should be considered a high priority and eventually achieved through collaborative efforts.
BACKGROUND: EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres. SUMMARY: The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Based on the EUSOMA requirements, a voluntary and accredited certification scheme has been developed. In Europe, other voluntary certification schemes are available, such as those developed by the German Cancer Society and German Society for Breast Disease, the National Cancer Peer Review Programme in the UK, and the "label de qualité" established by the Swiss Anticancer League and the Swiss Senology Society. The European Commission Initiative on Breast Cancer (ECIBC) has overseen the development of a European Quality Assurance Scheme. KEY MESSAGES: Nearly 20 years after the initial publication of the EUSOMA requirements, ensuring that all breast cancer patients in Europe are treated only in certified breast centres should be considered a high priority and eventually achieved through collaborative efforts.
Authors: L Cataliotti; A Costa; P A Daly; L Fallowfield; G Freilich; L Holmberg; M Piccart; C J van de Velde; U Veronesi Journal: Eur J Cancer Date: 1999-01 Impact factor: 9.162
Authors: Rachel A Greenup; Samilia Obeng-Gyasi; Samantha Thomas; K Houck; Whitney O Lane; Rachel C Blitzblau; Terry Hyslop; E Shelley Hwang Journal: Ann Surg Date: 2018-02 Impact factor: 12.969
Authors: Laura Biganzoli; Lorenza Marotti; Christopher D Hart; Luigi Cataliotti; Bruno Cutuli; Thorsten Kühn; Robert E Mansel; Antonio Ponti; Philip Poortmans; Peter Regitnig; Jos A van der Hage; Yvonne Wengström; Marco Rosselli Del Turco Journal: Eur J Cancer Date: 2017-09-28 Impact factor: 9.162
Authors: Mandy Kiderlen; Antonio Ponti; Mariano Tomatis; Petra G Boelens; Esther Bastiaannet; Robin Wilson; Cornelis J H van de Velde; Riccardo A Audisio Journal: Eur J Cancer Date: 2015-04-16 Impact factor: 9.162
Authors: D R Leff; C Ho; H Thomas; R Daniels; L Side; F Lambert; J Knight; M Griffiths; M Banwell; J Aitken; G Clayton; S Dua; A Shaw; S Smith; V Ramakrishnan Journal: Eur J Surg Oncol Date: 2015-04-15 Impact factor: 4.424
Authors: A R M Wilson; L Marotti; S Bianchi; L Biganzoli; S Claassen; T Decker; A Frigerio; A Goldhirsch; E G Gustafsson; R E Mansel; R Orecchia; A Ponti; P Poortmans; P Regitnig; M Rosselli Del Turco; E J Th Rutgers; C van Asperen; C A Wells; Y Wengström; L Cataliotti Journal: Eur J Cancer Date: 2013-08-19 Impact factor: 9.162
Authors: P A van Dam; M Tomatis; L Marotti; J Heil; R E Mansel; M Rosselli Del Turco; P J van Dam; D Casella; L G Bassani; M Danei; A Denk; D Egle; G Emons; K Friedrichs; N Harbeck; M Kiechle; R Kimmig; U Koehler; S Kuemmel; N Maass; C Mayr; A Prové; C Rageth; L Regolo; F Lorenz-Salehi; D Sarlos; C Singer; C Sohn; G Staelens; C Tinterri; R Audisio; A Ponti Journal: Eur J Cancer Date: 2017-09-04 Impact factor: 9.162